Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study was stopped (date of termination was 13April2011) due to a 6 month interim analysis: all of the 3 SAM-531 dosage levels were declared futile. There were no safety concerns.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of probable Alzheimer Disease according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Diseases and Related Disorders Association (NINCDS-ADRDA) criteria.
Mini-Mental State Examination (MMSE) score of 12 to 24 at screening
Rosen Modified Hachinski Ischemic score \< or equal to 4 at screening.
You may not be if
Relevant neurologic disease other than Alzheimer Disease that may affect cognition or ability to complete the study.
Current major depressive disorder or other current major psychiatric disorder.
History of clinically evident stroke or clinically important carotid or vertebrobasilar stenosis or plaque.
Use of prescription or nonprescription medications for cognitive enhancement (including memantine, ginkgo biloba, huperzine A, and cholinesterase inhibitors) within 3 months before the baseline visit.
